Transfer hydrogenation catalysis in cells as a new approach to anticancer drug design

Nature Communications

Volumn 6, Issue , 2015, Pages

  Soldevila Barreda, Joan J ^a   Romero Canelón, Isolda ^a   Habtemariam, Abraha ^a   Sadler, Peter J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FORMIC ACID; IRIDIUM; NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; RUTHENIUM(II)SULFONAMIDO ETHYLENEAMINE COMPLEX; UNCLASSIFIED DRUG; FORMIC ACID DERIVATIVE; ORGANOMETALLIC COMPOUND; RUTHENIUM DERIVATIVE;

CANCER; CATALYSIS; CATALYST; DESIGN; DRUG DEVELOPMENT; HYDROGEN; MEMBRANE; MITOCHONDRION; NEW RECORD; REDOX CONDITIONS;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CATALYSIS; CATALYST; DRUG DESIGN; FEMALE; HUMAN; HUMAN CELL; HYDROGENATION; HYDROPHOBICITY; MITOCHONDRIAL MEMBRANE POTENTIAL; OVARY CANCER; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PROTON NUCLEAR MAGNETIC RESONANCE; CARCINOMA; CELL LINE; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FIBROBLAST; METABOLISM; NECROSIS; OVARY TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CATALYSIS; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FIBROBLASTS; FORMATES; HUMANS; HYDROGENATION; NAD; NECROSIS; ORGANOMETALLIC COMPOUNDS; OVARIAN NEOPLASMS; RUTHENIUM COMPOUNDS;

EID: 84924313275     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7582     Document Type: Article

References (59)

1. 2: the influence of the alkylidene moiety on metathesis activity. J. Am. Chem. Soc. 118, 100-110 (1996).
2. 2] and its reactions. Angew. Chem. Int. Ed. 34, 2039-2041 (1995).
3. Hashiguchi, S. et al. Kinetic resolution of racemic secondary alcohols by Ru″-catalyzed hydrogen transfer. Angew. Chem. Int. Ed. 36, 288-290 (1997).
4. Haack, K. J., Hashiguchi, S., Fujii, A., Ikariya, T. & Noyori, R. The catalyst precursor, catalyst, and intermediate in the Ru″-promoted asymmetric hydrogen transfer between alcohols and ketones. Angew. Chem. Int. Ed. 36, 285-288 (1997).
5. Shen, D. W., Pouliot, L. M., Hall, M. D. & Gottesman, M. M. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 64, 706-721 (2012).
6. Abu-Surrah, A. S. & Kettunen, M. Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin. Cur. Med. Chem. 13, 1337-1357 (2006).
7. Furrer, J., Smith, G. S. & Therrien, B. in Inorganic Chemical Biology: Principles, Techniques and Applications (ed. Gasser, G.) 341-364 (Wiley, 2014).
8. Liu, Z. et al. The potent oxidant anticancer activity of organoiridium catalysts. Angew. Chem. Int. Ed. 53, 3941-3946 (2014).
9. Chenault, H. K. & Whitesides, G. M. Regeneration of nicotinamide cofactors for use in organic synthesis. Appl. Biochem. Biotechnol. 14, 147-197 (1987).
10. Wu, H. et al. Methods for the regeneration on NAD coenzymes. Green Chem. 15, 1773-1789 (2013).
11. Quinto, T., Köhler, V. & Ward, T. R. Recent trends in biomimetic NADH regeneration. Top. Catal. 57, 321-331 (2014).
12. +: structure-activity relationships and mechanistic aspects in the formation of the 1, 4-NADH derivatives. Angew. Chem. Int. Ed. 38, 1997-2000 (1999).
13. + models for tandem cofactor regeneration, horse liver alcohol dehydrogenase recognition of 1,4-NADH derivatives, and chiral synthesis. Angew. Chem. Int. Ed. 41, 478-481 (2002).
14. +: structure-activity relationships, kinetics, and mechanist. Inorg. Chem. 40, 6705-6716 (2001).
15. 2 as the precatalyst and sodium formate as the hydride source: Kinetic and activation parameters, and the significance of steric and electronic effects. J. Organomet. Chem. 695, 145-150 (2010).
16. + for selective organic synthesis. J. Organomet. Chem. 689, 4783-4790 (2004).
17. Canivet, J., Süss-Fink, G. & Štěpnička, P. Water-soluble phenanthroline complexes of rhodium, iridium and ruthenium for the regeneration of NADH in the enzymatic reduction of ketones. Eur. J. Inorg. Chem. 2007, 4736-4742 (2007).
18. Haquette, P. et al. Chemically engineered papain as artificial formate dehydrogenase for NAD(P)H regeneration. Org. Biomol. Chem. 9, 5720-5727 (2011).
19. de Torres, M., Dimroth, J., Arends, I. W. C. E., Keilitz, J. & Hollmann, F. Towards recyclable NAD(P)H regeneration catalysts. Molecules 17, 9835-9841 (2012).
20. +. Organometallics 31, 5958-5967 (2012).
21. + by ruthenium(II) arene complexes under biologically relevant conditions. J. Biol. Inorg. Chem. 11, 483-488 (2006).
22. Wu, X. et al. On water and in air: fast and highly chemoselective transfer hydrogenation of aldehydes with iridium catalysts. Angew. Chem. Int. Ed. 45, 6718-6722 (2006).
23. Tan, J. et al. pH-regulated transfer hydrogenation of quinoxalines with a Cp∗Ir-diamine catalyst in aqueous media. Tetrahedron 67, 6206-6213 (2011).
24. Bugarcic, T. et al. Cytotoxicity, cellular uptake, and DNA interactions of new monodentate ruthenium(II) complexes containing terphenyl arenes. J. Med. Chem. 51, 5310-5319 (2008).
25. Chen, H., Parkinson, J. A., Morris, R. E. & Sadler, P. J. Highly selective binding of organometallic ruthenium ethylenediamine complexes to nucleic acids: novel recognition mechanisms. J. Am. Chem. Soc. 173-186 (2003).
26. Chen, H. et al. Organometallic ruthenium(II) diamine anticancer complexes: arene-nucleobase stacking and stereospecific hydrogen-bonding in guanine adducts. J. Am. Chem. Soc. 124, 3064-3082 (2002).
27. Habtemariam, A. et al. Structure-activity relationships for cytotoxic ruthenium(II) arene complexes containing N,N-, N,O-, and O,O-chelating ligands. J. Med. Chem. 49, 6858-6868 (2006).
28. Wang, F., Xu, J., Habtemariam, A. & Sadler, P. J. Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate. J. Am. Chem. Soc. 127, 17734-17743 (2005).
29. Wang, F. et al. Competition between glutathione and DNA oligonucleotides for ruthenium(II) arene anticancer complexes. Dalton Trans. 42, 3188-3195 (2013).
30. Aird, R. E. et al. In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer. Br. J. Cancer 86, 1652-1657 (2002).
31. Wang, F. et al. Kinetics of aquation and anation of ruthenium(II) arene anticancer complexes, acidity and X-ray structures of aqua adducts. Chem. Eur. J. 9, 5810-5820 (2003).
32. Diehn, M. et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458, 780-783 (2009).
33. Jungwirth, U. et al. Anticancer activity of metal complexes: involvement of redox processes. Antioxid. Redox Signal. 15, 1085-1127 (2011).
34. Romero-Canelón, I. & Sadler, P. J. Next-generation metal anticancer complexes: multitargeting via redox modulation. Inorg. Chem. 52, 12276-12291 (2013).
35. Watson, J. Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol. 3, 1-9 (2013).
36. Trachootham, D., Alexandre, J. & Huang, P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat. Rev. Drug. Discov. 8, 579-591 (2009).
37. Betanzos-Lara, S. et al. Organometallic ruthenium and iridium transfer-hydrogenation catalysts using coenzyme NADH as a cofactor. Angew. Chem. Int. Ed. 51, 3897-3900 (2012).
38. Liu, Z. et al. Reduction of quinones by NADH catalyzed by organoiridium complexes. Angew. Chem. Int. Ed. 52, 4194-4197 (2013).
39. Bayir, H. et al. Apoptotic interactions of cytochrome c: redox flirting with anionic phospholipids within and outside of mitochondria. Biochim. Biophys. Acta 1757, 648-659 (2006).
40. Galluzzi, L. et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell Death 2012. Cell Death Differ. 19, 107-120 (2012).
41. Zhang, H. et al. Glutathione-dependent reductive stress triggers mitochondrial oxidation and cytotoxicity. FASEB J. 26, 1442-1451 (2012).
42. Hocharoen, L. & Cowan, J. A. Metallotherapeutics: novel strategies in drug design. Chem. Eur. J. 15, 8670-8676 (2009).
43. Li, J. & Chen, P. R. Moving Pd-mediated protein cross coupling to living systems. Chembiochem 13, 1728-1731 (2012).
44. Noffke, A. L., Habtemariam, A., Pizarro, A. M. & Sadler, P. J. Designing organometallic compounds for catalysis and therapy. Chem. Commun. 48, 5219-5246 (2012).
45. Sasmal, P. K., Streu, C. N. & Meggers, E. Metal complex catalysis in living biological systems. Chem. Commun. 49, 1581-1587 (2013).
46. Salvemini, D. et al. A nonpeptidyl mimic of superoxide dismutase with therapeutic activity in rats. Science 286, 304-306 (1999).
47. Filipović, M. R. et al. Striking inflammation from both sides: manganese(II) pentaazamacrocyclic SOD mimics act also as nitric oxide dismutases: a single-cell study. Angew. Chem. Int. Ed. 49, 4228-4232 (2010).
48. Sasmal, P. K. et al. Catalytic azide reduction in biological environments. Chem. Bio. Chem. 13, 1116-1120 (2012).
49. Bradford, S. & Cowan, J. A. Catalytic metallodrugs targeting HCV IRES RNA. Chem. Commun. 48, 3118-3120 (2012).
50. Lee, J. et al. Cleavage agents for a-synuclein. Bull. Korean Chem. Soc. 29, 882-884 (2008).
51. Suh, J. et al. Cleavage agents for soluble oligomers of human islet amyloid polypeptide. J. Biol. Inorg. Chem. 13, 693-701 (2008).
52. Suh, J. et al. Cleavage agents for soluble oligomers of amyloid beta peptides. Angew. Chem. Int. Ed. 46, 7064-7067 (2007).
53. Lee, T. Y. & Suh, J. Target-selective peptide-cleaving catalysts as a new paradigm in drug design. Chem. Soc. Rev. 38, 1949-1957 (2009).
54. Kayed, R. et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300, 486-489 (2003).
55. Dougan, S. J., Habtemariam, A., McHale, S. E., Parsons, S. & Sadler, P. J. Catalytic organometallic anticancer complexes. Proc. Natl Acad. Sci. USA 105, 11628-11633 (2008).
56. Streu, C. & Meggers, E. Ruthenium-induced allylcarbamate cleavage in living cells. Angew. Chem. Int. Ed. 45, 5645-5648 (2006).
57. Sasmal, P. K., Carregal-Romero, S., Parak, W. J. & Meggers, E. Light-triggered ruthenium-catalyzed allylcarbamate cleavage in biological environments. Organometallics 31, 5968-5970 (2012).
58. Völker, T., Dempwolff, F., Graumann, P. L. & Meggers, E. Progress towards bioorthogonal catalysis with organometallic compounds. Angew. Chem. Int. Ed. 53, 10536-10540 (2014).
59. Köhler, V. et al. Synthetic cascades are enabled by combining biocatalysts with artificial metalloenzymes. Nat. Chem. 5, 93-99 (2013).